Drug induced liver injury historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rachita Navara, M.D. [2]

Overview

Drug induced liver injury has been historically underreported.

Historical Perspective

Over the last fifty years, the United States Food and Drug Administration has withdrawn several drugs from the market for causing severe liver injury. Notably in 1997 to 1998, bromfenac and troglitazone were withdrawn from the market for causing severe hepatocellular injury. Drug induced liver injury remains the most frequent single cause of drug withdrawals from the market today.^[1]

References

↑ United States Food and Drug Administration. Guidance for Industry. http://www.fda.gov/downloads/Drugs/…/Guidances/UCM174090.pdf Accessed on October 24, 2016

[FDA1-1] United States Food and Drug Administration. Guidance for Industry. http://www.fda.gov/downloads/Drugs/…/Guidances/UCM174090.pdf Accessed on October 24, 2016

[1]